Trial Profile
A PHASE 1, RANDOMIZED, 2-WAY CROSSOVER, MULTIPLE DOSE, OPEN LABEL STUDY OF THE EFFECT OF PF-04965842 ON MIDAZOLAM PHARMACOKINETICS IN HEALTHY VOLUNTEERS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Abrocitinib (Primary) ; Midazolam
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 24 Oct 2018 Status changed from recruiting to completed.
- 03 Sep 2018 New trial record